Our previous work has confirmed that hypertriglyceridemia-driven kallistatin (KAL) elevation is present in the peripheral blood of patients with MASLD and diabetes and is a causative factor in hepatic steatosis and MASH pathogenesis. This evidence concerns the gene SERPINA4 and metabolic dysfunction-associated steatohepatitis.